Right now, in the UK and across the world, vaccines for Covid-19 are being rolled out. You may have already received, or be expecting a vaccination offer sometime soon. Vaccines are thought to be our main hope to control the Covid-19 pandemic. Their use has only been possible following robust and rigorous clinical trials, which have demonstrated that they meet high safety and effectiveness standards set by the UK medicines regulator (the MHRA).
Working in collaboration with: Dr Kirsty Alderton and Dr Frederico Magalhaes who offered mental health support for these focus groups.
What did you do?
There is a current lack of effective treatments for anorexia nervosa (an eating disorder characterised by weight loss, difficulties maintaining weight, and often a preoccupation with one’s own body weight and shape). With fewer than half of those diagnosed with anorexia making a full recovery, there is a desperate need for new treatment avenues to be explored.
Lillie Pakzad-Shahabi, Clinical Trial Coordinator, Neuro-oncology, Department of Medicine, Imperial College London
Why did you decide to do Patient and Public Involvement (PPI) in your clinical trial?
After receiving a NIHR Imperial BRC PPI award (Round 3) to run a project with a secondary school, I stumbled across the PERC-ICTU PPI training series at Imperial. These workshops helped me to understand the importance of PPI early in clinical trial design. I decided it would be useful to involve patients from our clinic and their family members to review upcoming clinical trial protocols.
We hoped to gather the perspectives of patients and their family members on our plans for the design of two clinical trials.